RESEARCH
Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRCResearch published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops. (JCO Precision Oncology)